Simulations Plus, Inc. (NASDAQ:SLP) announced a quarterly dividend on Wednesday, July 10th, NASDAQ reports. Shareholders of record on Thursday, July 25th will be given a dividend of 0.06 per share by the technology company on Thursday, August 1st. This represents a $0.24 dividend on an annualized basis and a yield of 0.69%. The ex-dividend date is Wednesday, July 24th.
Simulations Plus has increased its dividend payment by an average of 6.3% per year over the last three years and has increased its dividend every year for the last 2 years. Simulations Plus has a dividend payout ratio of 60.0% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect Simulations Plus to earn $0.63 per share next year, which means the company should continue to be able to cover its $0.24 annual dividend with an expected future payout ratio of 38.1%.
Shares of SLP opened at $34.87 on Tuesday. The stock’s 50-day moving average is $28.83. The firm has a market capitalization of $600.10 million, a PE ratio of 77.79 and a beta of -0.39. Simulations Plus has a 12 month low of $17.18 and a 12 month high of $36.20.
In related news, Chairman Walter S. Woltosz sold 18,500 shares of the business’s stock in a transaction dated Friday, April 26th. The stock was sold at an average price of $22.11, for a total value of $409,035.00. Following the transaction, the chairman now owns 5,196,039 shares in the company, valued at $114,884,422.29. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 31.57% of the company’s stock.
A number of research analysts have commented on SLP shares. ValuEngine upgraded Valmont Industries from a “sell” rating to a “hold” rating in a research note on Friday, July 12th. BidaskClub upgraded Workhorse Group from a “hold” rating to a “buy” rating in a research note on Monday, July 15th. Finally, Zacks Investment Research upgraded Hallmark Financial Services from a “hold” rating to a “buy” rating and set a $16.00 price objective on the stock in a research note on Friday.
Simulations Plus Company Profile
Simulations Plus, Inc develops drug discovery and development software for mechanistic modeling and simulation, and machine-learning-based prediction of properties of molecules from their structure worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments that measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments.
Featured Article: What is a stock portfolio tracker?
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.